Loading…
Reported covered position: L.A., Rep Xavier Becerra (2000-2001)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
American Health Care Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
American Health Care Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2017 · second_quarter · Q2
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Corporate tax reform proposals including proposed board adjustment tax.
Source: Senate LDA
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
FAST Generics Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
FAST Generics Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Lower Drug Costs through Competition Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Lower Drug Costs through Competition Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Affordable and Safe Prescription Drug Importation Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Affordable and Safe Prescription Drug Importation Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Improving Access To Affordable Prescription Drugs Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Improving Access To Affordable Prescription Drugs Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2016 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
PATIENT Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Combination Drug Development Incentive Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Combination Drug Development Incentive Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Combination Drug Development Incentive Act of 2015
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2016 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Combination Drug Development Incentive Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Combination Drug Development Incentive Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Helping Families in Mental Health Crisis Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Helping Families in Mental Health Crisis Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Safeguarding America's Pharmaceuticals Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B
Stop Tampering of Prescription Pills Act of 2013
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Preserve Access to Affordable Generics Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Pharmaceutical Quality, Security, and Accountability Act
Client: TEVA PHARMACEUTICALS USA INC · Firm: TEVA PHARMACEUTICALS USA, INC.
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2017 · first_quarter · Q1
Corporate tax reform proposals including proposed board adjustment tax.
HR 1628-American Health Care Act; Medicaid Rebate provision of the Bipartisan Budget Act of 2015; draft of the Creating & Restoring Equal Access to Equivalent Samples Act ("CREATES Act") for 2017; HR 2051-FAST Generics Act; S.637-C-THRU Act; S.771-Improving Access to Affordable Drugs Act; Importation Amdt. to Senate Budget Resolution; S.469-Affordable and Safe Prescription Drug Importation Act; and HR 749-Lower Drugs Through Competition Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · fourth_quarter · 4A
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Patent reform proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · fourth_quarter · Q4
Patent reform proposals.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · third_quarter · Q3
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.
Patent reform proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · second_quarter · Q2
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Patent reform proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2016 · first_quarter · Q1
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Patent reform proposals.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2015 · fourth_quarter · Q4
Patent reform proposals.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2016 Labor, HHS & Related Agencies Appropriations; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2015 · third_quarter · Q3
Patent reform proposals.
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2015 · second_quarter · Q2
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; and drug pricing proposals and issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2015 · first_quarter · Q1
Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2016 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; HR 406, Combination Drug Development Incentive Act of 2015; "21st Century Cures" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Drug pricing proposals and issues.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2014 · fourth_quarter · Q4
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2014 · third_quarter · Q3
Prescription Drug Abuse, STOPP Act HR486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; counterfeit drugs; HR 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H. 3717 Helping Families in Mental Health Crisis Act of 2013; HR4800, FY15 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies;HR 2985, Combinaation Drug Development Incentive Act of 2013; and "21st Century Cures."
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2014 · second_quarter · Q2
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2014 · first_quarter · Q1
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act; H.R. 3717 Helping Families in Mental Health Crisis Act of 2013.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · fourth_quarter · Q4
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · third_quarter · Q3
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · second_quarter · Q2
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B; counterfeit drugs: "track-and-trace," H.R. 1919, Safeguarding America's Pharmaceuticals Act, and S.959, Pharmaceutical Quality, Security and Accountability Act.
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · first_quarter · 1A
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B
Ttemporarily suspend the duty on S-(2-benzothiazolyl)-2-(2-amino-thiazol-4-yl)-2-acetoxyimino thiocetate (Thioester).
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
TEVA PHARMACEUTICALS USA INC via TEVA PHARMACEUTICALS USA, INC.
2013 · first_quarter · Q1
S.214, Preserve Access to Affordable Generics Act; and S.504, A bill to amend the Federal Food, Drug and Cosmetic Act to ensure that valid generic drugs may enter the market
Prescription Drug Abuse, STOPP Act H.R.486; S.Con.Res.8 (FY 2014 Budget) (provisions relating to healthcare and pharmeceuticals); Drug labeling, electronic labeling proposals; access to contraceptives, Plan B
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office